Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia

Sponsor
Ono Pharmaceutical Co. Ltd (Industry)
Overall Status
Completed
CT.gov ID
NCT00417326
Collaborator
(none)
174
9
2
19.3

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the safety and efficacy of ONO-5046Na in patients with acute respiratory failure associated with community-acquired pneumonia

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
174 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
ONO-5046Na Phase II Study - A Pilot Study for Patients With Acute Respiratory Failure
Study Start Date :
Dec 1, 2006
Actual Primary Completion Date :
Aug 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: P

Drug: ONO-5046Na
twenty four hour infusion at 0 mg/kg/hr for 14 days

Experimental: E

Drug: ONO-5046Na
twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days

Outcome Measures

Primary Outcome Measures

  1. pulmonary function [14 days]

Secondary Outcome Measures

  1. mortality [28 days]

  2. ventilator status [28 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 79 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with community-acquired pneumonia

  • Patients with acute respiratory failure

Exclusion Criteria:
  • Patients with nosocomial pneumonia

  • Patients on mechanical ventilation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chubu Region Chubu Japan
2 Chugoku Region Chugoku Japan
3 Hokkaido Region Hokkaido Japan
4 Hokuriku Region Hokuriku Japan
5 Kanto Region Kanto Japan
6 Kinki Region Kinki Japan
7 Kyushu Region Kyushu Japan
8 Shikoku Region Shikoku Japan
9 Tohoku Region Tohuku Japan

Sponsors and Collaborators

  • Ono Pharmaceutical Co. Ltd

Investigators

  • Study Director: Koji Takehara, Ono Pharmaceutical Co. Ltd

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ono Pharmaceutical Co. Ltd
ClinicalTrials.gov Identifier:
NCT00417326
Other Study ID Numbers:
  • ONO-5046Na-14
First Posted:
Jan 1, 2007
Last Update Posted:
Jun 13, 2012
Last Verified:
Jun 1, 2012
Keywords provided by Ono Pharmaceutical Co. Ltd
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 13, 2012